EUCTR2008-006844-21-GB进行中（未招募）不适用
Evaluation of a developmental ‘long lasting’ emollient in subjects with dry skin.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects fulfilling all the following criteria are eligible for inclusion in the study:
- •Eczema sufferers. Females with essentially ‘non-hairy’ arms and legs, aged between 18 and 65 years of age. Subjects with medically dry skin to arms and lower legs and with baseline corneometer measurements differing by no more than 5 units between left and right arms and legs. Subjects willing to adopt an essentially sedentary lifestyle for the duration of study involvement (i.e. those willing to refrain from participating in any sports or significant physical activity likely to necessitate showering/bathing more often than once daily). Subjects giving their written and witnessed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects falling into any of the following criteria will not be eligible for the study:
- •Subjects with any significant concurrent illness or skin disease currently involving arms or legs. Subjects with a history of skin disease or allergy relevant to the study. Subjects who have known allergies to the test products or their ingredients. Subjects using any topical or systemic medication, or drug, likely to affect the skin response to the test medicines.
- •Subjects showing any significant visible skin abnormality or hair growth at the test measurement sites considered likely to interfere with corneometry. Subjects who have participated in an irritation test, on the same skin sites, in the past month, or a sensitisation test, on any skin site, during the past 3 months. Females who are lactating or may be pregnant or if of childbearing potential and are not taking adequate contraceptive precautions. Subjects who are concurrently participating in any other safety or efficacy test. Subjects with any irritation, tattoos, scars or birthmarks at the test sites. Subjects not willing to refrain from removing leg hair (by shaving, waxing, depilation etc.) for at least 48 hours prior to study participation and for the duration of the study. Subjects who have used oral and topical steroids for any condition within the previous 4 weeks. Employees of RSSL Pharma or Dermal Laboratories, or an immediate family member (partner, offspring, parents, siblings or sibling’s offspring) of such employees.
研究者
相似试验
已完成
4 期
A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis.10014982Atopic DermatitisNL-OMON30879Astellas Pharma120
已完成
2 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Christmas disease1006447710005330NL-OMON54158CSL Behring LLC6
进行中（未招募）
1 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Haemophilia BMedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2020-000739-28-DKuniQure biopharma B.V.10
招募中
1 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Haemophilia BMedDRA version: 20.0Level: LLTClassification code: 10018939Term: Haemophilia B (Factor IX) Class: 10010331CTIS2024-512603-39-00CSL Behring LLC9
招募中
2 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.2024-512603-39-00CSL Behring LLC9